Santen Pharmaceutical Co., Ltd. (4536.T)
JPY 1548.0
(-0.51%)
JPY 1548.0
(-0.51%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 301.96 Billion | 279.03 Billion | 266.25 Billion | 249.6 Billion | 241.55 Billion | 234.02 Billion |
| Cost of Revenue | 138.08 Billion | 112.95 Billion | 109.67 Billion | 98.22 Billion | 94.83 Billion | 90.76 Billion |
| Gross Profit | 163.87 Billion | 166.08 Billion | 156.58 Billion | 151.38 Billion | 146.72 Billion | 143.26 Billion |
| Operating Expenses | 111.97 Billion | 169.17 Billion | 120.7 Billion | 138.46 Billion | 113.18 Billion | 98.16 Billion |
| Selling, General and Administrative Expenses | 87.27 Billion | 96.25 Billion | 84.49 Billion | 79.55 Billion | 73.36 Billion | 71.27 Billion |
| Research and Development Expenses | 24.7 Billion | 28.29 Billion | 26.37 Billion | 24.11 Billion | 23.34 Billion | 23.75 Billion |
| Other Expenses | - | - | 9.82 Billion | 34.8 Billion | 16.48 Billion | 3.13 Billion |
| Cost and Expenses | 250.06 Billion | 282.12 Billion | 230.37 Billion | 236.68 Billion | 208.02 Billion | 188.92 Billion |
| Operating Income | 38.54 Billion | -3.09 Billion | 35.88 Billion | 12.91 Billion | 33.53 Billion | 45.09 Billion |
| Interest Expense | 2.66 Billion | 1.49 Billion | 1.2 Billion | 1.48 Billion | 2.39 Billion | 2.88 Billion |
| Income Tax Expense | 3.17 Billion | 9.18 Billion | 8.42 Billion | 5.77 Billion | 10.37 Billion | 11.17 Billion |
| Earnings before Tax | 37.44 Billion | -5.79 Billion | 35.61 Billion | 12.41 Billion | 32.09 Billion | 43.11 Billion |
| Net Income | 26.64 Billion | -14.94 Billion | 27.21 Billion | 6.83 Billion | 23.61 Billion | 31.94 Billion |
| Earnings Per Share Basic | 72.62 | -38.58 | 68.07 | 17.10 | 59.16 | 78.64 |
| Earnings Per Share Diluted | 72.37 | -38.58 | 67.97 | 17.06 | 59.01 | 78.41 |
| Weighted Average Shares Outstanding | 366.89 Million | 387.42 Million | 399.77 Million | 399.45 Million | 399.15 Million | 406.16 Million |
| Weighted Average Shares Outstanding (Diluted) | 368.13 Million | 387.42 Million | 400.45 Million | 400.38 Million | 400.25 Million | 407.39 Million |
| Gross Margin | 0.54 | 0.60 | 0.59 | 0.61 | 0.61 | 0.61 |
| EBIT Margin | 0.19 | 0.05 | 0.20 | 0.12 | 0.21 | 0.24 |
| Profit Margin | 0.09 | -0.05 | 0.10 | 0.03 | 0.10 | 0.14 |
| EBITDA | 56.45 Billion | 14.29 Billion | 54.52 Billion | 30 Billion | 49.41 Billion | 54.09 Billion |
| Earnings Before Tax Margin | 0.13 | -0.01 | 0.13 | 0.05 | 0.14 | 0.19 |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | 74.77 Billion | 301.96 Billion | 79.13 Billion | 77.02 Billion | 73.41 Billion | 72.38 Billion |
| Cost of Revenue | 32 Billion | 138.08 Billion | 34.04 Billion | 32.14 Billion | 29.43 Billion | 30.02 Billion |
| Gross Profit | 42.76 Billion | 163.87 Billion | 45.08 Billion | 44.88 Billion | 43.98 Billion | 42.36 Billion |
| Operating Expenses | 29.61 Billion | 111.97 Billion | 33.98 Billion | 33.82 Billion | 31.63 Billion | 29.61 Billion |
| Selling, General and Administrative Expenses | 21.37 Billion | - | 26.78 Billion | 21.57 Billion | 22.1 Billion | 21.06 Billion |
| Research and Development Expenses | 5.5 Billion | - | 7.2 Billion | 5.74 Billion | 6.15 Billion | 6.3 Billion |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 61.61 Billion | 250.06 Billion | 68.03 Billion | 65.96 Billion | 61.06 Billion | 59.63 Billion |
| Operating Income | 13.15 Billion | 51.9 Billion | 11.1 Billion | 11.05 Billion | 12.35 Billion | 12.75 Billion |
| Interest Expense | 407 Million | 2.66 Billion | 1.68 Billion | 703 Million | 486 Million | 168 Million |
| Income Tax Expense | 2.84 Billion | 3.17 Billion | -3.8 Billion | 2.17 Billion | 2.34 Billion | 2.45 Billion |
| Earnings before Tax | 13.45 Billion | 37.44 Billion | 960 Million | 9.48 Billion | 11.2 Billion | 12.86 Billion |
| Net Income | 10.63 Billion | 26.64 Billion | 29 Million | 7.33 Billion | 8.86 Billion | 10.41 Billion |
| Earnings Per Share Basic | 29.61 | - | 0.08 | 20.73 | 24.60 | 27.93 |
| Earnings Per Share Diluted | 29.50 | - | 0.08 | 20.66 | 24.52 | 27.85 |
| Weighted Average Shares Outstanding | 360.44 Million | 366.89 Million | 363.2 Million | 353.62 Million | 360.45 Million | 372.78 Million |
| Weighted Average Shares Outstanding (Diluted) | 360.44 Million | 368.13 Million | 363.2 Million | 354.92 Million | 361.6 Million | 373.97 Million |
| Gross Margin | 0.57 | 0.54 | 0.57 | 0.58 | 0.60 | 0.59 |
| EBIT Margin | 0.24 | - | 0.20 | 0.19 | 0.23 | 0.24 |
| Profit Margin | 0.14 | 0.09 | 0.00 | 0.10 | 0.12 | 0.14 |
| EBITDA | 17.86 Billion | - | 15.66 Billion | 14.87 Billion | 16.59 Billion | 17.06 Billion |
| Earnings Before Tax Margin | 0.18 | 0.17 | 0.14 | 0.14 | 0.17 | 0.18 |
0JT5
688396
0688
MNTHF
ANORA
RETO